Medical imaging-based companion diagnostics for solid tumors

Yin, Rui; Zhang, Qingpeng; Liao, Shiyi; Lu, Chang; Zhang, Cheng; Cai, Qingyun; Song, Guosheng

doi:10.1016/j.engmed.2024.100009

Cited by 2 publications

(1 citation statement)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This targeted release of active therapeutics enhances the efficacy of cancer treatment while minimizing systemic toxicity ( Knox et al, 1995 ; Güngör et al, 2019 ; Güngör et al, 2020 ; Tokay et al, 2020 ). In parallel, diagnostic probes, including fluorescent dyes, imaging agents, or nanoparticles, can be incorporated into the prodrug structure to enable real-time monitoring of drug activation and tumor response to therapy ( McNerney et al, 2021 ; Rajapaksha et al, 2024 ; Yin et al, 2024 ).…”

Section: Distinct Advantages Of Nitroreductase Activable Agentsmentioning

confidence: 99%

Recent advances and applications of nitroreductase activable agents for tumor theranostic

Shang,

Yu,

Wang

2024

Front. Pharmacol.

View full text Add to dashboard Cite

Nitroreductase activable agents offer a personalized and targeted approach to cancer theranostics by selectively activating prodrugs within the tumor microenvironment. These agents enable non-invasive tumor imaging, image-guided drug delivery, and real-time treatment monitoring. By leveraging the enzymatic action of tumor-specific nitroreductase enzymes, cytotoxic drugs are delivered directly to cancer cells while minimizing systemic toxicity. This review highlights the key features, mechanisms of action, diagnostic applications, therapeutic potentials, and future directions of nitroreductase activable agents for tumor theranostics. Integration with imaging modalities, advanced drug delivery systems, immunotherapy combinations, and theranostic biomarkers shows promise for optimizing treatment outcomes and improving patient survival in oncology. Continued research and innovation in this field are crucial for advancing novel theranostic strategies and enhancing patient care. Nitroreductase activable agents represent a promising avenue for personalized cancer therapy and have the potential to transform cancer diagnosis and treatment approaches.

show abstract

Section: Distinct Advantages Of Nitroreductase Activable Agentsmentioning

confidence: 99%

Recent advances and applications of nitroreductase activable agents for tumor theranostic

Shang,

Yu,

Wang

2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

Self-Activated Cascade-Tailored Small Molecule for Cancer Therapy, Companion Diagnostics, and “Theranostic Correlation” Evaluation

Dong,

Wang,

Tong

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Companion diagnostics (CDx) have emerged as valuable tools for monitoring biomarkers essential for drug activation and therapeutic response, enabling personalized treatment strategies. However, the current FDA-approved CDx is limited to in vitro testing, making it challenging to assess the realtime drug efficacy. Moreover, evaluation of treatment responses solely based on drug release or activation may disregard tumor heterogeneity. To address these challenges, we have developed a cascade-responsive small molecule Cbl-DEVD-Hcy for simultaneous cancer therapy and the timely evaluation of therapy effectiveness in vivo. Upon cleavage by tumor-cell-overexpressed carboxylesterase, chlorambucil (Cbl) can be released to induce tumor cell apoptosis and activate caspase-3. This activation triggers the production of the near-infrared dye Hcy-NH 2 , generating both near-infrared fluorescence and photoacoustic signals for monitoring the apoptosis process. The excellent "theranostic correlation" between the imaging signal and therapeutic response, as demonstrated in orthotopic breast tumors, highlights the potential of Cbl-DEVD-Hcy for effective tumor therapy and precise CDx in the body.

show abstract

Medical imaging-based companion diagnostics for solid tumors

Cited by 2 publications

References 149 publications

Recent advances and applications of nitroreductase activable agents for tumor theranostic

Recent advances and applications of nitroreductase activable agents for tumor theranostic

Self-Activated Cascade-Tailored Small Molecule for Cancer Therapy, Companion Diagnostics, and “Theranostic Correlation” Evaluation

Contact Info

Product

Resources

About